Emerging immunotargets and immunotherapies in prostate cancer

Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi, Marina Scarpelli

Research output: Contribution to journalArticle

8 Scopus citations


Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.

Original languageEnglish (US)
Pages (from-to)777-782
Number of pages6
JournalCurrent Drug Targets
Issue number7
StatePublished - Jun 1 2016


  • Immunotherapy
  • Prognosis
  • Programmed death-1
  • Prostate cancer
  • Vaccines

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Emerging immunotargets and immunotherapies in prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Montironi, R., Santoni, M., Sotte, V., Cheng, L., Lopez-Beltran, A., Massari, F., Matrana, M. R., Moch, H., Berardi, R., & Scarpelli, M. (2016). Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets, 17(7), 777-782.